|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Wyeth |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002266 |
Purpose
To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.
| Condition | Intervention |
|---|---|
|
HIV Infections |
Drug: AS-101 |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label |
| Official Title: | An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients |
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Concurrent Medication:
Excluded without permission of Wyeth-Ayerst medical monitor:
Patients with the following are excluded:
Prior Medication:
Excluded within 4 weeks of study entry:
Patients must:
Contacts and Locations
More Information
| Study ID Numbers: | 045B, 753A-103-US |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002266 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Drug Therapy, Combination Acquired Immunodeficiency Syndrome AIDS-Related Complex ammonium trichloro(dioxoethylene-O,O'-)tellurute |
|
Sexually Transmitted Diseases, Viral Radiation-Protective Agents Immunologic Factors Acquired Immunodeficiency Syndrome Adjuvants, Immunologic AIDS-Related Complex Antiviral Agents |
Immunologic Deficiency Syndromes Virus Diseases HIV Infections Ammonium trichloro(dioxoethylene-O,O'-)tellurate Sexually Transmitted Diseases Retroviridae Infections |
|
Anti-Infective Agents Radiation-Protective Agents RNA Virus Infections Sexually Transmitted Diseases, Viral Slow Virus Diseases Immunologic Factors Immune System Diseases Antineoplastic Agents Physiological Effects of Drugs Acquired Immunodeficiency Syndrome Adjuvants, Immunologic Infection |
Protective Agents Antiviral Agents Pharmacologic Actions Immunologic Deficiency Syndromes Virus Diseases HIV Infections Ammonium trichloro(dioxoethylene-O,O'-)tellurate Therapeutic Uses Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections |